Mirvetuximab soravtansine is used to treat adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who are no longer responding to platinum-based chemotherapy and have received 1 to 3 types of chemotherapy.

Your doctor will perform a tests to make sure mirvetuximab soravtansine is the right treatment for you.

Mirvetuximab soravtansine may also be used for purposes not listed in this medication guide.

Tell your doctor if you have or have ever had:

• vision or eye problems; or
• liver problems.

May harm an unborn baby. Do not use if you are pregnant. Use effective birth control while using mirvetuximab soravtansine and for at least 7 months after your last dose. Tell your doctor if you become pregnant.

You may need to have a negative pregnancy test before starting this treatment.

Do not breastfeed while using this medicine, and for at least 1 month after your last dose.

Use Mirvetuximab Soravtansine (Intravenous) exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended.

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

• dry eyes, sensitivity to light, blurred vision, eye pain, or new or worsening vision changes;
• cough, chest pain, trouble breathing, shortness of breath; or
• numbness, tingling, or burning pain in your hands or feet.

Common side effects may include:

• abnormal lab results;
• nausea, stomach pain, diarrhea, constipation;
• fever, mouth sores, skin sores, sore throat, cough; or
• pale skin, tiredness, feeling light-headed or short of breath, cold hands and feet.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Avoid wearing contact lenses while using mirvetuximab soravtansine unless your doctor tells you to.